Insulin aspart SAR341402

DRUG2 trials

Sponsors

Sanofi

Conditions

Type 1 Diabetes Mellitus

Phase 1

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

CompletedNCT03436498

SanofiType 1 Diabetes Mellitus

Start: 2018-05-10End: 2018-10-06Updated: 2022-04-25

Phase 3

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

CompletedNCT03874715

SanofiType 1 Diabetes Mellitus

Start: 2019-03-11End: 2020-07-08Updated: 2024-04-17

Related Papers

137-LB: Safety Assessment of SAR341402 and NovoLog When Administered through an Insulin Pump

Diabetes2019-06-01